Dev Prasad
Stock Analyst at LUCID CAPITAL MARKETS
(3.14)
# 1,102
Out of 5,182 analysts
6
Total ratings
60%
Success rate
121.88%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dev Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATYR aTyr Pharma | Downgrades: Neutral | $11 → $1 | $0.79 | +26.44% | 1 | Sep 15, 2025 | |
| CUE Cue Biopharma | Initiates: Buy | $120 | $17.93 | +569.27% | 1 | Aug 25, 2025 | |
| IRD Opus Genetics | Initiates: Buy | $5 | $5.12 | -2.34% | 1 | Jun 17, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Buy | $24 | $14.42 | +66.44% | 1 | Dec 17, 2024 | |
| IBIO iBio, Inc. | Initiates: Buy | $6 | $1.71 | +250.88% | 1 | Dec 17, 2024 | |
| CALC CalciMedica | Initiates: Buy | $13 | $0.59 | +2,103.02% | 1 | Dec 17, 2024 |
aTyr Pharma
Sep 15, 2025
Downgrades: Neutral
Price Target: $11 → $1
Current: $0.79
Upside: +26.44%
Cue Biopharma
Aug 25, 2025
Initiates: Buy
Price Target: $120
Current: $17.93
Upside: +569.27%
Opus Genetics
Jun 17, 2025
Initiates: Buy
Price Target: $5
Current: $5.12
Upside: -2.34%
Avalo Therapeutics
Dec 17, 2024
Initiates: Buy
Price Target: $24
Current: $14.42
Upside: +66.44%
iBio, Inc.
Dec 17, 2024
Initiates: Buy
Price Target: $6
Current: $1.71
Upside: +250.88%
CalciMedica
Dec 17, 2024
Initiates: Buy
Price Target: $13
Current: $0.59
Upside: +2,103.02%